PM
CBAY

Prosight Management’s Cymabay Therapeutics CBAY Stock Holding History

Prosight Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-93,923
Closed -$292K – 37
2022
Q1 		$292K Sell
93,923
-72,852
-44% -$229K 0.19% 32
2021
Q4 		$564K Buy
+166,775
New +$633K 0.34% 32

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Prosight Management's CBAY Position: Q2 2022 in Review

Prosight Management sold out of Cymabay Therapeutics (CBAY) in Q2 2022, closing a stake of 93,923 shares — an estimated $292K sold.

Prosight Management first reported a position in CBAY in Q4 2021 and held it in 2 quarters. The position peaked at $564K in Q4 2021. 106 funds tracked by Wall St. Rank hold CBAY as of Q2 2022.

  • Prosight Management reported no remaining Cymabay Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Prosight Management sold 93,923 Cymabay Therapeutics shares in Q2 2022, an estimated $292K.
  • Prosight Management first reported a position in Cymabay Therapeutics in Q4 2021 and held it in 2 quarters.
  • Prosight Management's Cymabay Therapeutics position peaked at $564K in Q4 2021.
  • 106 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2022.

Based on Prosight Management's 13F filing for Q2 2022, filed 12 Aug 2022.